BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome
Feb 20 (Reuters) - Soleno Therapeutics Inc (SLNO.O) :
* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME
* SOLENO THERAPEUTICS INC - MINUTES OF MEETING CONFIRMED FDA, CO ALIGNED ON ALL KEY ASPECTS OF CO'S PLANNED PHASE III CLINICAL TRIAL FOR DCCR
Source text for Eikon: Further company coverage: (SLNO.O)
